Sarah is the Chief Investment Officer at Archangels, and has direct responsibility for number of the portfolio companies, particularly those focused on healthcare. Archangels is a prominent business angel syndicate which has been at the forefront of early stage investing in Scotland for more than a quarter of a century. It comprises more than 100 investor members and typically co-ordinates the investment of more than £15 million per year in exciting early stage Scottish companies. Sarah has extensive international experience of financing early stage opportunities in the technology sector, with specific focus in life science and healthcare arena. Prior to Archangels, Sarah worked at the Wellcome Trust, Advent Life Sciences team and Parke-Davis Neuroscience Research Centre and has a PhD from the University of Aberdeen.